Sinotau Pharmaceutical Group

This study tests a new PET imaging method that uses a special tracer called XTR003 along with FDG to see which parts of the heart are still alive in people with heart failure from blocked arteries. About 40 to 60 participants will be randomly assigned to receive either the new fa…

This phase 3 trial tests whether an injection called XTR004, used with a PET scan, can accurately detect blood flow-blocking narrowings in heart arteries. About 395 adults with known or suspected stable coronary artery disease will receive the injection and undergo imaging. The r…

This early-stage trial is testing a new imaging agent called Flotufolastat F-18 in 6 healthy Chinese adults. The tracer is designed to light up prostate cancer cells during PET scans. Researchers are checking how safe it is, where it goes in the body, and how much radiation it gi…